TH
Impact Report 2024-25
£20.8m raised in 2024-25; 83p in every £1 spent went directly to supporting patients; commitment to invest up to £30m in research by 2030 to treble the number of patients participating in clinical trials
Key Metric 1
Clinical trial patient Jan Ross is in complete remission from multiple myeloma following charity-funded early-phase trial; patient John McGartland in remission from gastro-oesophageal junction cancer following RNA immunotherapy trial